Basilea Pharmaceutica Ltd. Logo



BAL3833 (also known as CCT3833) is an oral small-molecule drug candidate (panRAF/SRC kinase inhibitor) targeting cell proliferation signaling pathways that are associated with tumor growth and the development of resistance to current therapies. It is currently being evaluated in a clinical phase 1 dose-escalation study in adult patients with advanced solid tumors, including metastatic melanoma.

BAL3833 is the lead compound of a series of kinase inhibitors in-licensed by Basilea in April 2015. The compound originates from research at The Institute of Cancer Research and the Cancer Research UK Manchester Institute, by scientists funded by Cancer Research UK and the Wellcome Trust.